Blog

Oct 24, 2024, 13:05

Concurrent thoracic radiotherapy improves the PFS and OS with acceptable toxicity in EGFR-mutated NSCLC

Gustavo Viani shared a post on Linkedin:

”Concurrent thoracic radiotherapy improves the PFS and OS with acceptable and tolerable toxicity in patients with EGFR-mutated oligo-organ metastatic NSCLC.

Target OBJECTIVE
• Investigate whether combining first-line lung cancer (TRT) with EGFR-TKIs high survival compared to EGFR-TKIs alone in patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer (NSCLC)

Laboratory METHODS :
• Multicenter, randomized, phase III trial (Northern Radiation Oncology Group of China-002)
• 118 patients enrolled between April 2016 and February 2022
• patients in the TKI + lung cancer group received 60 Gy cancer to primary tumors and positive regional lymph nodes
• PFS was the first endpoint, with OS and treatment-related adverse events (TRAEs) as second endpoints

RESULTS:
• High The TKI + lung cancer group had significantly better outcomes:
• High PFS: 17.1 months vs 10.6 months (TKI alone); HR 0.57, P = .004
• High OS: 34.4 months vs 26.2 months (TKI alone); HR 0.62, P = .029.
• local control but high incidence of severe TRAEs (11.9% vs 5.1%).”

Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non–Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial

Authors: Hongfu Sun, Minghao Li, Wei Huang, Jian Zhang, Shihong Wei, Yongjing Yang, ZhongtangWang, Shucheng Ye, Heyi Gong, Yaowen Zhang, Jie Li, Haixia Song, Lifang Wang, XiangmingChen, Haiqun Lin, Gaofeng Ding, Hongwei Li, Anping Zheng, Xuezhen Ma, ShaoShui Chen, Liping Liu, Kaixian Zhang, Chengrui Fu, Wenzhi Liu, Jing Wang, Xiaqin Zhang, Tingting Liu, Dan Han, QianZhao, Peipei Wu, Qianqian Yuan, LiJun Tian, Ping Zhang, Xueqin Wu, Fei Chen, Zicheng Zhang and Baosheng Li.

Concurrent thoracic radiotherapy improves the PFS and OS with acceptable toxicity in EGFR-mutated NSCLC

Gustavo Viani, MD is an Associate Professor in the Department of Medical Imaging, Hematology, and Oncology at Hospital das Clínicas, Faculty of Medicine of Ribeirão Preto, University of São Paulo (FMRP-USP). Dr. Viani’s research focuses on radiation oncology, with expertise in brachytherapy, stereotactic radiosurgery, dose fractionation, radiation tolerance, and overall oncology practices.

Anping Zheng Baosheng Li cancer cancer treatment Chengrui Fu clinical trials Dan Han EGFR EGFR-mutated Fei Chen Gaofeng Ding Gustavo Viani Haiqun Lin Haixia Song Heyi Gong Hongfu Sun Hongwei Li Jian Zhang Jie Li Jing Wang Kaixian Zhang Lifang Wang LiJun Tian Liping Liu Lung cancer Minghao Li NSCLC OncoDaily Oncology oncology research Peipei Wu Ping Zhang Qianqian Yuan QianZhao radiotherapy ShaoShui Chen Shihong Wei Shucheng Ye Tingting Liu TKIs Wei Huang Wenzhi Liu XiangmingChen Xiaqin Zhang Xueqin Wu Xuezhen Ma Yaowen Zhang Yongjing Yang ZhongtangWang Zicheng Zhang

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage